Older adults are being warned against receiving the chikungunya vaccine before traveling.
The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind.
The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus.
But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.
“FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq,” the release reads.
Hellbound and Down 